Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 2/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15417421 | 0.80 | CA2 (0.36) | ALDH1A1RECQLKCNA3LTA4HTAAR1 | |
| SCHEMBL20710739 | 0.79 | LTA4H (0.49) | ALDH1A1RECQLKCNA3LTA4HTDP1 | |
| SCHEMBL685508 | 0.79 | ALDH1A1 (0.54) | ALDH1A1RECQLGAAKCNA3LTA4H | |
| SCHEMBL685567 | 0.78 | ALDH1A1 (0.46) | ALDH1A1RECQLGAAKCNA3LTA4H | |
| SCHEMBL195903 | 0.77 | LTA4H (0.43) | ALDH1A1RECQLKCNA3LTA4HTAAR1 | |
| SCHEMBL8939051 | 0.77 | LTA4H (0.39) | KCNA3LTA4HTDP1TSHRCYP3A4 | |
| SCHEMBL16822398 | 0.77 | ALDH1A1 (0.52) | ALDH1A1RECQLGAAKCNA3LTA4H | |
| SCHEMBL8939022 | 0.73 | DRD2 (0.37) | ALDH1A1LTA4HMEN1KMT2ATSHR | |
| SCHEMBL8938994 | 0.71 | LTA4H (0.41) | LTA4HTDP1 | |
| SCHEMBL8939020 | 0.70 | CA4 (0.44) | KCNA3LTA4HKMT2ATDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309167-B2 | Process for oligomerization of olefins that uses a catalytic composition that comprises an organometallic complex that contains an alkoxy ligand that is functionalized by a heteroatom | IFP Energies Nouvelles (FR) | 2016-04-12 | — | — | US | disclosed |
| US-9309167-B2 | Process for oligomerization of olefins that uses a catalytic composition that comprises an organometallic complex that contains an alkoxy ligand that is functionalized by a heteroatom | IFP Energies Nouvelles (FR) | 2016-04-12 | — | — | US | disclosed |
| US-8624042-B2 | Process for dimerization of ethylene to but-1-ene using a composition comprising a titanium-based complex and an alkoxy ligand functionalized by a heteroatom | IFP Energies Nouvelles (FR) | 2014-01-07 | — | — | US | disclosed |
| US-8624042-B2 | Process for dimerization of ethylene to but-1-ene using a composition comprising a titanium-based complex and an alkoxy ligand functionalized by a heteroatom | IFP Energies Nouvelles (FR) | 2014-01-07 | — | — | US | disclosed |
| US-20130217941-A1 | PROCESS FOR OLIGOMERIZATION OF OLEFINS THAT USES A CATALYTIC COMPOSITION THAT COMPRISES AN ORGANOMETALLIC COMPLEX THAT CONTAINS AN ALKOXY LIGAND THAT IS FUNCTIONALIZED BY A HETEROATOM | IFP Energies Nouvelles (FR) | 2013-08-22 | — | — | US | disclosed |
| US-20130217941-A1 | PROCESS FOR OLIGOMERIZATION OF OLEFINS THAT USES A CATALYTIC COMPOSITION THAT COMPRISES AN ORGANOMETALLIC COMPLEX THAT CONTAINS AN ALKOXY LIGAND THAT IS FUNCTIONALIZED BY A HETEROATOM | IFP Energies Nouvelles (FR) | 2013-08-22 | — | — | US | disclosed |
| US-20110288308-A1 | PROCESS FOR DIMERIZATION OF ETHYLENE TO BUT-1-ENE USING A COMPOSITION COMPRISING A TITANIUM-BASED COMPLEX AND AN ALKOXY LIGAND FUNCTIONALIZED BY A HETEROATOM | IFP Energies nouvelle (FR) | 2011-11-24 | — | — | US | disclosed |
| US-20110288308-A1 | PROCESS FOR DIMERIZATION OF ETHYLENE TO BUT-1-ENE USING A COMPOSITION COMPRISING A TITANIUM-BASED COMPLEX AND AN ALKOXY LIGAND FUNCTIONALIZED BY A HETEROATOM | IFP Energies nouvelle (FR) | 2011-11-24 | — | — | US | disclosed |
| US-20110287927-A1 | PROCESS FOR OLIGOMERIZATION OF OLEFINS THAT USES A CATALYTIC COMPOSITION THAT COMPRISES AN ORGANOMETALLIC COMPLEX THAT CONTAINS AN ALKOXY LIGAND THAT IS FUNCTIONALIZED BY A HETEROATOM | IFP Energies Nouvelles (FR) | 2011-11-24 | — | — | US | disclosed |
| US-20110287927-A1 | PROCESS FOR OLIGOMERIZATION OF OLEFINS THAT USES A CATALYTIC COMPOSITION THAT COMPRISES AN ORGANOMETALLIC COMPLEX THAT CONTAINS AN ALKOXY LIGAND THAT IS FUNCTIONALIZED BY A HETEROATOM | IFP Energies Nouvelles (FR) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288308-A1 | PROCESS FOR DIMERIZATION OF ETHYLENE TO BUT-1-ENE USING A COMPOSITION COMPRISING A TITANIUM-BASED COMPLEX AND AN ALKOXY LIGAND FUNCTIONALIZED BY A HETEROATOM | AS3MT, ALK, AP2M1 | ALDH1A1 1420/4885RECQL 4701/4885GAA 2154/4885 |
| US-20110287927-A1 | PROCESS FOR OLIGOMERIZATION OF OLEFINS THAT USES A CATALYTIC COMPOSITION THAT COMPRISES AN ORGANOMETALLIC COMPLEX THAT CONTAINS AN ALKOXY LIGAND THAT IS FUNCTIONALIZED BY A HETEROATOM | CPNE4, HAO2, AP2M1 | ALDH1A1 2242/4885RECQL 4423/4885GAA 3560/4885 |
| US-20130217941-A1 | PROCESS FOR OLIGOMERIZATION OF OLEFINS THAT USES A CATALYTIC COMPOSITION THAT COMPRISES AN ORGANOMETALLIC COMPLEX THAT CONTAINS AN ALKOXY LIGAND THAT IS FUNCTIONALIZED BY A HETEROATOM | CPNE4, HAO2, AP2M1 | ALDH1A1 2242/4885RECQL 4423/4885GAA 3560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.